TranspoCART19
Sponsors
Fundacion De Investigacion Biomedica De Salamanca, Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz, Clinica Universidad De Navarra, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Conditions
Lupus NephritisLupus Nephritis (LN)Refractory Lupus NephritisRelapsed or refractory B-cell lymphomarefractory or resistant CD19+ acute lymphoblastic leukemia
Phase 1
Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.
RecruitingCTIS2024-514544-90-00
Start: 2024-03-11Target: 27Updated: 2025-12-02
Single-center phase I/IIa study of infusion of autologous peripheral blood T cells expanded and genetically modified by Sleeping Beauty family transposons to express a chimeric antigen receptor with anti-CD19 specificity conjugated with the 4-1BB costimulatory region and CD3z and huEGFRt signal transmission (TranspoCART19) in patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment
Not yet recruitingCTIS2025-522673-11-00
Target: 24Updated: 2026-01-02
Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.
Not yet recruitingCTIS2025-522449-23-00
Target: 10Updated: 2026-06-11
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
Not yet recruitingNCT07799116
Start: 2026-09-01End: 2030-09-01Target: 10Updated: 2026-09-02